Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 152Lymphoma, Mantle-Cell 30Lymphoma, Non-Hodgkin 22Lymphoma, Follicular 22Lymphoma 22Recurrence 21Neoplasms, Plasma Cell 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Leukemia, Myeloid, Acute 12Waldenstrom Macroglobulinemia 11Lymphoma, Large B-Cell, Diffuse 11Immunoglobulin Light-chain Amyloidosis 10Neoplasms 8Lymphoma, B-Cell, Marginal Zone 8Leukemia, Lymphocytic, Chronic, B-Cell 8Lymphoma, B-Cell 7Leukemia 6Carcinoma, Non-Small-Cell Lung 6Myelodysplastic Syndromes 5Hematologic Neoplasms 5Brain Neoplasms 5Amyloidosis 5Lymphoma, Large-Cell, Immunoblastic 4Hematologic Diseases 4Congenital Abnormalities 4Prostatic Neoplasms 3Paraproteinemias 3Leukemia, Myelomonocytic, Acute 3Leukemia, Monocytic, Acute 3Leukemia, Erythroblastic, Acute 3

Interventions

Dexamethasone 4pomalidomide 2dexamethasone acetate 2dexamethasone 21-phosphate 2daratumumab 2auricularum 2Calcium Dobesilate 2Bortezomib 2navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1ixazomib 1carfilzomib 1Specimen Handling 1Peripheral Blood Stem Cell Transplantation 1Panobinostat 1Melphalan 1Lenalidomide 1Gemcitabine 1Busulfan 1Biopsy 12-(5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-(1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Plasmacytoma × Bortezomib × Clear all
NCT02136134 2025-08-29

Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

Janssen Research & Development, LLC

Phase 3 Completed
498 enrolled 15 charts
Plasma cell

Multiple Myeloma, Plasmacytoma

NCT00569868 2011-08-12

UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple Myeloma

University of Arkansas

Phase NA Completed
11 enrolled 4 charts
Plasma cell

Multiple Myeloma, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡